737:
132:
66:
25:
234:
940:
This program supports a combination of mentors and MS postdoctoral training institutions to recruit and train MS rehabilitation fellows. Mentors are required to be experienced MS researchers who have an established and active participation in their field. Interested parties must submit an application
981:
High-risk pilot research programs focus on cutting-edge ideas and methods that have not been tested and may contribute to MS medical research. The Pilot
Research Grants provide one year of research funding to pilot programs in order to develop results which can be used to apply for long term funding
892:
Fast
Forward is a commercial research funding entity under the NMSS which provides funding for drug development and MS research being conducted through commercial entities such as EMD Pharmaceuticals, the University of Cambridge, the University of Edinburgh, and others. Researchers interested in the
880:
The NMSS offers funding to research centers with the intent to promote interaction among researchers. The
Collaborative MS Research Center Awards program is intended to create collaboration between MS researchers, including independent investigators, and clinical research organizations. In addition,
871:
The Career
Transition Fellowship program sponsors postdoctoral training and research funding for scientists who demonstrate a dedication to MS research. Awards are in amounts up to $ 550,000 for a total of five years of training and research. The training period covers two years and research funding
913:
was a researcher in the field of neuroscience who had a dedication to MS research. He was the
Director of Research at NMSS from 1966 to 1977. The scholarship in his name is offered to provide salary and research funding for a period of five years to researchers who are beginning their careers in MS
800:
founded in 1946. It is an organization dedicated to supporting individuals affected by multiple sclerosis (MS) and funding research to find a cure for the disease. They provide resources, support services, advocacy efforts, and educational programs to improve the lives of people with MS and their
931:
The
International Progressive MS Alliance was founded in 2012 as the International Progressive MS Collaborative. The MS Alliance membership is composed of MS organizations from around the world. The Alliance provides two different funding awards, including the Challenge Award and Collaborative
972:
and NMSS have partnered to develop this grant program. The program focuses on providing grant funding to MS researchers. In 2016, the
American Academy of Neuroscience Clinician Scientist Development Program awarded $ 3 million to research and training programs with a focus on neuroscience.
851:
Throughout two two-day meetings in 2014–2015, the NMSS developed the
Wellness Research Working Group and wellness research priorities. The Research Wellness Group provides information regarding self-directed approaches for disease management to people diagnosed with multiple sclerosis.
922:
The Health Care
Delivery and Policy Research (HCDPR) program funds investigators who are conducting research projects which address NMSS organization's priorities. These priorities are listed by the NMSS as funding, quality, outcomes, and costs for care related to MS.
901:
This award was named after a member of the Board of
Directors of the NMSS. Its purpose was to provide funding for training of MS researchers who needed additional education regarding the disease. As of 2017, this award was on hold and not accepting applications.
817:. a lawyer seeking a cure for her brother, Bernard, who suffered from multiple sclerosis. Recognizing the absence of any existing foundation or organization aiding individuals with (MS), Ms. Lawry established NMSS.
848:
to find out whether they are effective in treating MS. In 2012, the Society invested $ 44 million in more than 350 new and ongoing projects. As of 2016, NMSS has raised $ 974 million for research.
1187:
1711:
858:
consist of several types of contributions to researchers in early to late stages of their careers. The following is a list of awards distributed by NMSS to researchers in 2017.
248:
1909:
460:
1802:
1309:
1090:
Motl, Robert W; Mowry, Ellen M; Ehde, Dawn M; LaRocca, Nicholas G; Smith, Kathy E; Costello, Kathleen; Shinto, Lynne; Ng, Alexander V; Sullivan, Amy B (2017-01-12).
1889:
76:
1368:
1066:
1147:
1512:
149:
38:
824:, the organization funds research, advocates for social and political change, offers educational resources, and sponsors services that help people with
1701:
196:
1797:
844:
The NMSS supports and funds research activities in early research, translational research that develops laboratory results into treatments, and
168:
953:
1899:
1195:
775:
175:
1361:
597:
252:
91:
1894:
932:
Network Award grants. Both grants provide funding over multiple years to researchers and institutions in the international community.
1904:
1749:
182:
1853:
1386:
450:
44:
1233:
1092:"Wellness and multiple sclerosis: The National MS Society establishes a Wellness Research Working Group and research priorities"
164:
1858:
1734:
1681:
1354:
1868:
1673:
1047:
1833:
1759:
1719:
561:
881:
the program reaches out to professionals working in other fields of research to recruit them into MS research projects.
945:
642:
605:
746:
292:
274:
215:
113:
52:
1863:
1792:
1739:
1729:
1686:
1540:
1507:
1487:
768:
632:
470:
367:
1828:
1460:
256:
189:
95:
1744:
1656:
637:
489:
153:
969:
949:
445:
420:
83:
1823:
1787:
1482:
884:
MS Research Center Awards are obtained through an application process through the NMSS MS Grants web page.
566:
1175:
910:
761:
581:
576:
333:
1022:
1346:
493:
440:
338:
1724:
1609:
1399:
586:
380:
362:
465:
1444:
719:
142:
243:
may contain an excessive amount of intricate detail that may interest only a particular audience
1378:
1004:
797:
709:
1078:
893:
program are able to apply for funding through the Commercial Funding Opportunities web page.
455:
1767:
1691:
1424:
507:
415:
343:
813:
as the Association for Advancement of Research on Multiple Sclerosis on March 11, 1946 by
8:
1595:
1517:
741:
390:
1257:
1696:
1580:
1575:
1570:
1560:
1124:
1091:
1023:"National Multiple Sclerosis Society on the Forbes The 100 Largest U.S. Charities List"
957:
825:
702:
323:
1772:
1555:
1465:
1129:
1111:
833:
542:
502:
385:
1234:"Mentor-Based Postdoctoral Fellowship in Rehabilitation Research | Research Funding"
1497:
1119:
1103:
678:
673:
537:
410:
1807:
1777:
512:
1782:
1472:
1434:
1310:"Announcing the 2016 American Academy of Neurology Research Program Recipients"
845:
714:
688:
571:
87:
1883:
1630:
1115:
1107:
821:
810:
527:
375:
832:
ranked the organization 63rd among the 100 largest U.S. charities. In 2017,
255:
any relevant information, and removing excessive detail that may be against
1590:
1133:
814:
647:
591:
517:
1605:
1600:
1545:
683:
1376:
1209:
1649:
1585:
1565:
1550:
1524:
1409:
665:
532:
308:
1176:
https://researchfunding.duke.edu/daniel-haughton-senior-faculty-awards
872:
covers three additional years for research in a new faculty position.
836:
awarded the organization three out of four stars for its performance.
1625:
1620:
1429:
1414:
1148:"List of Current Research Projects Funded by the National MS Society"
522:
1067:
List of Current Research Projects Funded by the National MS Society.
914:
research. The program is most often supported through universities.
131:
1615:
1404:
1339:
1419:
652:
328:
1394:
829:
1282:"Home – Office of Sponsored Projects – The University of Utah"
917:
809:
The National Multiple Sclerosis Society (NMSS) was founded in
1439:
935:
887:
1803:
Megalencephalic leukoencephalopathy with subcortical cysts
1188:"International Progressive MS Alliance | Challenge Awards"
875:
905:
963:
926:
1281:
896:
1048:"When Donating to MS Causes, Where Does the Money Go?"
861:
1513:
Lesional demyelinations of the central nervous system
1089:
94:, and by adding encyclopedic content written from a
1910:
Disability organizations based in the United States
156:. Unsourced material may be challenged and removed.
1702:Chronic inflammatory demyelinating polyneuropathy
1881:
1890:Non-profit organizations based in New York City
1798:Leukoencephalopathy with vanishing white matter
866:
954:University of Colorado Anschutz Medical Campus
1362:
769:
918:Health Care Delivery & Policy Contracts
53:Learn how and when to remove these messages
1369:
1355:
941:for the program through the NMSS website.
776:
762:
1750:Experimental autoimmune encephalomyelitis
1210:"International Progressive MS Alliance |"
1123:
293:Learn how and when to remove this message
275:Learn how and when to remove this message
216:Learn how and when to remove this message
114:Learn how and when to remove this message
1854:List of multiple sclerosis organizations
976:
944:Participants in the program include the
936:Mentor-based Postdoctoral Rehabilitation
888:Fast Forward commercial/drug development
960:, and additional related institutions.
876:Collaborative MS Research Center Awards
1882:
1859:List of people with multiple sclerosis
1735:Neuromyelitis optica spectrum disorder
1682:Neuromyelitis optica spectrum disorder
1045:
906:Harry Weaver Neuroscience Scholarships
368:Individualized Education Program (IEP)
75:contains content that is written like
1350:
1307:
1303:
1301:
1258:"National Multiple Sclerosis Society"
964:Clinician Scientist Development Award
927:International Progressive MS Alliance
643:Disabled Peoples' International (DPI)
165:"National Multiple Sclerosis Society"
1900:1946 establishments in New York City
1834:Mitochondrial DNA depletion syndrome
1720:Acute disseminated encephalomyelitis
999:
997:
995:
897:Daniel Haughton Senior Faculty Award
562:Social Security Disability Insurance
227:
154:adding citations to reliable sources
125:
59:
18:
1155:National Multiple Sclerosis Society
862:Research funding and grant programs
790:National Multiple Sclerosis Society
13:
1298:
946:Duke University School of Medicine
606:Ontario Disability Support Program
14:
1921:
1895:Organizations established in 1946
1331:
992:
34:This article has multiple issues.
1905:Multiple sclerosis organizations
1864:Multiple sclerosis drug pipeline
1740:Diffuse myelinoclastic sclerosis
1730:Marburg acute multiple sclerosis
1687:Diffuse myelinoclastic sclerosis
1541:Management of multiple sclerosis
1508:Radiologically isolated syndrome
1488:Expanded Disability Status Scale
1308:Neurology, American Academy of.
736:
735:
633:National Telecommuting Institute
232:
130:
64:
23:
1461:Diagnosis of multiple sclerosis
1274:
1250:
1226:
1202:
141:needs additional citations for
42:or discuss these issues on the
16:American nonprofit organization
1745:Tumefactive multiple sclerosis
1657:Research in multiple sclerosis
1377:Demyelinating diseases of the
1180:
1169:
1140:
1083:
1072:
1060:
1039:
1015:
638:Society for Disability Studies
490:Unlicensed assistive personnel
1:
1214:www.progressivemsalliance.org
1192:www.progressivemsalliance.org
1046:Tobias, Ed (September 2017).
985:
970:American Academy of Neurology
950:Weizmann Institute of Science
828:and their families. In 2016,
1824:Central pontine myelinolysis
1793:Pelizaeus–Merzbacher disease
1788:Metachromatic leukodystrophy
1483:Clinically isolated syndrome
1454:Investigations and diagnosis
867:Career Transition Fellowship
567:Supplemental Security Income
329:Ableism / Disablism
257:Knowledge's inclusion policy
7:
1829:Marchiafava–Bignami disease
839:
820:With chapters spanning the
582:Disabled students allowance
577:Disability Living Allowance
10:
1926:
1096:Multiple Sclerosis Journal
804:
441:Disability rights movement
1846:
1816:
1758:
1725:Balo concentric sclerosis
1710:
1672:
1665:
1639:
1533:
1453:
1385:
587:Disabled Persons Railcard
1238:researchfunding.duke.edu
1108:10.1177/1352458516687404
600:the Severely Handicapped
556:Socioeconomic assistance
466:Sexuality and disability
720:Disability in the media
1666:Demyelinating diseases
1379:central nervous system
798:nonprofit organization
710:Disability in the arts
528:Physical accessibility
977:Pilot Research Grants
456:People-first language
434:Societal implications
96:neutral point of view
1768:Adrenoleukodystrophy
1692:MOG antibody disease
1494:Serological and CSF
1445:Uhthoff's phenomenon
523:Orthotics and braces
508:Assistive technology
150:improve this article
1596:Monomethyl fumarate
1009:National MS Society
484:Personal assistance
391:Learning disability
88:promotional content
1697:Multiple sclerosis
1581:Interferon beta-1b
1576:Interferon beta-1a
1571:Glatiramer acetate
1561:Diroximel fumarate
1534:Approved treatment
1387:Signs and symptoms
1314:www.prnewswire.com
1262:www.weizmann.ac.il
958:University of Utah
826:multiple sclerosis
598:Assured Income for
90:and inappropriate
1877:
1876:
1842:
1841:
1773:Alexander disease
1556:Dimethyl fumarate
1498:Oligoclonal bands
1466:McDonald criteria
834:Charity Navigator
796:) is an American
786:
785:
543:Web accessibility
503:Accessible toilet
386:Special education
324:Disability theory
317:Theory and models
303:
302:
295:
285:
284:
277:
226:
225:
218:
200:
124:
123:
116:
57:
1917:
1670:
1669:
1640:Other treatments
1518:Dawson's fingers
1371:
1364:
1357:
1348:
1347:
1343:
1342:
1340:Official website
1325:
1324:
1322:
1321:
1305:
1296:
1295:
1293:
1292:
1278:
1272:
1271:
1269:
1268:
1254:
1248:
1247:
1245:
1244:
1230:
1224:
1223:
1221:
1220:
1206:
1200:
1199:
1194:. Archived from
1184:
1178:
1173:
1167:
1166:
1164:
1162:
1152:
1144:
1138:
1137:
1127:
1087:
1081:
1079:Research We Fund
1076:
1070:
1064:
1058:
1057:
1055:
1054:
1043:
1037:
1036:
1034:
1033:
1019:
1013:
1012:
1001:
856:Research rewards
778:
771:
764:
739:
738:
679:Paralympic Games
674:Special Olympics
538:Universal design
461:Pejorative terms
305:
304:
298:
291:
280:
273:
269:
266:
260:
236:
235:
228:
221:
214:
210:
207:
201:
199:
158:
134:
126:
119:
112:
108:
105:
99:
77:an advertisement
68:
67:
60:
49:
27:
26:
19:
1925:
1924:
1920:
1919:
1918:
1916:
1915:
1914:
1880:
1879:
1878:
1873:
1869:Pathophysiology
1838:
1812:
1808:CAMFAK syndrome
1778:Canavan disease
1754:
1706:
1661:
1635:
1529:
1449:
1381:
1375:
1338:
1337:
1334:
1329:
1328:
1319:
1317:
1316:(Press release)
1306:
1299:
1290:
1288:
1280:
1279:
1275:
1266:
1264:
1256:
1255:
1251:
1242:
1240:
1232:
1231:
1227:
1218:
1216:
1208:
1207:
1203:
1186:
1185:
1181:
1174:
1170:
1160:
1158:
1150:
1146:
1145:
1141:
1088:
1084:
1077:
1073:
1065:
1061:
1052:
1050:
1044:
1040:
1031:
1029:
1021:
1020:
1016:
1003:
1002:
993:
988:
979:
966:
938:
929:
920:
908:
899:
890:
878:
869:
864:
846:clinical trials
842:
807:
782:
751:
725:
724:
705:
695:
694:
693:
668:
658:
657:
628:
627:
611:
610:
602:
599:
557:
549:
548:
547:
513:Assisted living
485:
477:
476:
475:
435:
427:
426:
425:
405:
397:
396:
395:
358:
350:
349:
348:
318:
299:
288:
287:
286:
281:
270:
264:
261:
247:Please help by
246:
237:
233:
222:
211:
205:
202:
159:
157:
147:
135:
120:
109:
103:
100:
81:
69:
65:
28:
24:
17:
12:
11:
5:
1923:
1913:
1912:
1907:
1902:
1897:
1892:
1875:
1874:
1872:
1871:
1866:
1861:
1856:
1850:
1848:
1844:
1843:
1840:
1839:
1837:
1836:
1831:
1826:
1820:
1818:
1814:
1813:
1811:
1810:
1805:
1800:
1795:
1790:
1785:
1783:Krabbe disease
1780:
1775:
1770:
1764:
1762:
1756:
1755:
1753:
1752:
1747:
1742:
1737:
1732:
1727:
1722:
1716:
1714:
1708:
1707:
1705:
1704:
1699:
1694:
1689:
1684:
1678:
1676:
1667:
1663:
1662:
1660:
1659:
1654:
1653:
1652:
1643:
1641:
1637:
1636:
1634:
1633:
1628:
1623:
1618:
1613:
1610:+hyaluronidase
1603:
1598:
1593:
1588:
1583:
1578:
1573:
1568:
1563:
1558:
1553:
1548:
1543:
1537:
1535:
1531:
1530:
1528:
1527:
1522:
1521:
1520:
1515:
1510:
1502:
1501:
1500:
1492:
1491:
1490:
1485:
1476:
1475:
1473:Poser criteria
1470:
1469:
1468:
1457:
1455:
1451:
1450:
1448:
1447:
1442:
1437:
1435:Optic neuritis
1432:
1427:
1422:
1417:
1412:
1407:
1402:
1397:
1391:
1389:
1383:
1382:
1374:
1373:
1366:
1359:
1351:
1345:
1344:
1333:
1332:External links
1330:
1327:
1326:
1297:
1273:
1249:
1225:
1201:
1198:on 2015-09-18.
1179:
1168:
1157:. January 2017
1139:
1102:(3): 262–267.
1082:
1071:
1059:
1038:
1014:
990:
989:
987:
984:
978:
975:
965:
962:
937:
934:
928:
925:
919:
916:
907:
904:
898:
895:
889:
886:
877:
874:
868:
865:
863:
860:
841:
838:
806:
803:
784:
783:
781:
780:
773:
766:
758:
755:
754:
753:
752:
750:
749:
744:
732:
727:
726:
723:
722:
717:
715:Disability art
712:
706:
701:
700:
697:
696:
692:
691:
689:Invictus Games
686:
681:
676:
670:
669:
664:
663:
660:
659:
656:
655:
650:
645:
640:
635:
629:
626:
625:
622:
618:
617:
616:
613:
612:
609:
608:
603:
596:
594:
589:
584:
579:
574:
572:Ticket to Work
569:
564:
558:
555:
554:
551:
550:
546:
545:
540:
535:
530:
525:
520:
515:
510:
505:
499:
498:
497:
486:
483:
482:
479:
478:
474:
473:
471:Women's health
468:
463:
458:
453:
448:
443:
437:
436:
433:
432:
429:
428:
424:
423:
418:
413:
407:
406:
403:
402:
399:
398:
394:
393:
388:
383:
381:Special school
378:
372:
371:
370:
365:
359:
356:
355:
352:
351:
347:
346:
341:
336:
331:
326:
320:
319:
316:
315:
312:
311:
301:
300:
283:
282:
240:
238:
231:
224:
223:
206:September 2008
138:
136:
129:
122:
121:
92:external links
72:
70:
63:
58:
32:
31:
29:
22:
15:
9:
6:
4:
3:
2:
1922:
1911:
1908:
1906:
1903:
1901:
1898:
1896:
1893:
1891:
1888:
1887:
1885:
1870:
1867:
1865:
1862:
1860:
1857:
1855:
1852:
1851:
1849:
1845:
1835:
1832:
1830:
1827:
1825:
1822:
1821:
1819:
1815:
1809:
1806:
1804:
1801:
1799:
1796:
1794:
1791:
1789:
1786:
1784:
1781:
1779:
1776:
1774:
1771:
1769:
1766:
1765:
1763:
1761:
1757:
1751:
1748:
1746:
1743:
1741:
1738:
1736:
1733:
1731:
1728:
1726:
1723:
1721:
1718:
1717:
1715:
1713:
1709:
1703:
1700:
1698:
1695:
1693:
1690:
1688:
1685:
1683:
1680:
1679:
1677:
1675:
1671:
1668:
1664:
1658:
1655:
1651:
1648:
1647:
1645:
1644:
1642:
1638:
1632:
1631:Teriflunomide
1629:
1627:
1624:
1622:
1619:
1617:
1614:
1611:
1607:
1604:
1602:
1599:
1597:
1594:
1592:
1589:
1587:
1584:
1582:
1579:
1577:
1574:
1572:
1569:
1567:
1564:
1562:
1559:
1557:
1554:
1552:
1549:
1547:
1544:
1542:
1539:
1538:
1536:
1532:
1526:
1523:
1519:
1516:
1514:
1511:
1509:
1506:
1505:
1504:Radiological
1503:
1499:
1496:
1495:
1493:
1489:
1486:
1484:
1481:
1480:
1478:
1477:
1474:
1471:
1467:
1464:
1463:
1462:
1459:
1458:
1456:
1452:
1446:
1443:
1441:
1438:
1436:
1433:
1431:
1428:
1426:
1423:
1421:
1418:
1416:
1413:
1411:
1408:
1406:
1403:
1401:
1398:
1396:
1393:
1392:
1390:
1388:
1384:
1380:
1372:
1367:
1365:
1360:
1358:
1353:
1352:
1349:
1341:
1336:
1335:
1315:
1311:
1304:
1302:
1287:
1283:
1277:
1263:
1259:
1253:
1239:
1235:
1229:
1215:
1211:
1205:
1197:
1193:
1189:
1183:
1177:
1172:
1156:
1149:
1143:
1135:
1131:
1126:
1121:
1117:
1113:
1109:
1105:
1101:
1097:
1093:
1086:
1080:
1075:
1068:
1063:
1049:
1042:
1028:
1024:
1018:
1010:
1006:
1000:
998:
996:
991:
983:
974:
971:
961:
959:
955:
951:
947:
942:
933:
924:
915:
912:
903:
894:
885:
882:
873:
859:
857:
853:
849:
847:
837:
835:
831:
827:
823:
822:United States
818:
816:
812:
811:New York City
802:
799:
795:
791:
779:
774:
772:
767:
765:
760:
759:
757:
756:
748:
745:
743:
734:
733:
731:
730:
729:
728:
721:
718:
716:
713:
711:
708:
707:
704:
699:
698:
690:
687:
685:
682:
680:
677:
675:
672:
671:
667:
662:
661:
654:
651:
649:
646:
644:
641:
639:
636:
634:
631:
630:
624:Organizations
623:
620:
619:
615:
614:
607:
604:
601:
595:
593:
590:
588:
585:
583:
580:
578:
575:
573:
570:
568:
565:
563:
560:
559:
553:
552:
544:
541:
539:
536:
534:
531:
529:
526:
524:
521:
519:
516:
514:
511:
509:
506:
504:
501:
500:
495:
491:
488:
487:
481:
480:
472:
469:
467:
464:
462:
459:
457:
454:
452:
451:Normalization
449:
447:
444:
442:
439:
438:
431:
430:
422:
419:
417:
414:
412:
409:
408:
401:
400:
392:
389:
387:
384:
382:
379:
377:
376:Special needs
374:
373:
369:
366:
364:
363:Mainstreaming
361:
360:
354:
353:
345:
342:
340:
337:
335:
334:Medical model
332:
330:
327:
325:
322:
321:
314:
313:
310:
307:
306:
297:
294:
279:
276:
268:
258:
254:
250:
244:
241:This article
239:
230:
229:
220:
217:
209:
198:
195:
191:
188:
184:
181:
177:
174:
170:
167: –
166:
162:
161:Find sources:
155:
151:
145:
144:
139:This article
137:
133:
128:
127:
118:
115:
107:
97:
93:
89:
85:
79:
78:
73:This article
71:
62:
61:
56:
54:
47:
46:
41:
40:
35:
30:
21:
20:
1712:Inflammatory
1591:Mitoxantrone
1425:Incontinence
1318:. Retrieved
1313:
1289:. Retrieved
1286:osp.utah.edu
1285:
1276:
1265:. Retrieved
1261:
1252:
1241:. Retrieved
1237:
1228:
1217:. Retrieved
1213:
1204:
1196:the original
1191:
1182:
1171:
1159:. Retrieved
1154:
1142:
1099:
1095:
1085:
1074:
1062:
1051:. Retrieved
1041:
1030:. Retrieved
1026:
1017:
1008:
980:
967:
943:
939:
930:
921:
911:Harry Weaver
909:
900:
891:
883:
879:
870:
855:
854:
850:
843:
819:
815:Sylvia Lawry
808:
793:
789:
787:
648:Visitability
592:Freedom Pass
518:Mobility aid
416:Occupational
344:Other models
339:Social model
289:
271:
262:
249:spinning off
242:
212:
203:
193:
186:
179:
172:
160:
148:Please help
143:verification
140:
110:
104:January 2014
101:
86:by removing
82:Please help
74:
50:
43:
37:
36:Please help
33:
1606:Ocrelizumab
1601:Natalizumab
1546:Alemtuzumab
1005:"Our Story"
684:Deaflympics
533:Prosthetics
1884:Categories
1760:Hereditary
1674:Autoimmune
1650:Daclizumab
1586:Laquinimod
1566:Fingolimod
1551:Cladribine
1525:Frexalimab
1410:Dysarthria
1400:Depression
1320:2017-05-13
1291:2017-05-13
1267:2017-05-13
1243:2017-05-13
1219:2017-05-13
1053:2021-04-06
1032:2017-05-12
986:References
982:programs.
801:families.
742:Disability
666:Parasports
309:Disability
253:relocating
176:newspapers
84:improve it
39:improve it
1626:Siponimod
1621:Ponesimod
1479:Clinical
1430:Nystagmus
1415:Dysphagia
1116:1352-4585
1069:May 2015
446:Inclusion
357:Education
265:June 2024
45:talk page
1616:Ozanimod
1405:Diplopia
1134:28080254
840:Research
411:Physical
1646:Former
1420:Fatigue
1161:May 12,
1125:5494005
805:History
703:Culture
653:WeThe15
492: (
404:Therapy
190:scholar
1395:Ataxia
1132:
1122:
1114:
1027:Forbes
948:, the
830:Forbes
740:
621:Groups
421:Speech
192:
185:
178:
171:
163:
1847:Other
1817:Other
1151:(PDF)
747:Lists
197:JSTOR
183:books
1440:Pain
1163:2017
1130:PMID
1112:ISSN
968:The
794:NMSS
788:The
494:ADLs
169:news
1120:PMC
1104:doi
251:or
152:by
1886::
1312:.
1300:^
1284:.
1260:.
1236:.
1212:.
1190:.
1153:.
1128:.
1118:.
1110:.
1100:24
1098:.
1094:.
1025:.
1007:.
994:^
956:,
952:,
48:.
1612:)
1608:(
1370:e
1363:t
1356:v
1323:.
1294:.
1270:.
1246:.
1222:.
1165:.
1136:.
1106::
1056:.
1035:.
1011:.
792:(
777:e
770:t
763:v
496:)
296:)
290:(
278:)
272:(
267:)
263:(
259:.
245:.
219:)
213:(
208:)
204:(
194:·
187:·
180:·
173:·
146:.
117:)
111:(
106:)
102:(
98:.
80:.
55:)
51:(
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
